Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Indivior Pharmaceuticals (INDV) Receivables - Net (2021 - 2025)

Indivior Pharmaceuticals has reported Receivables - Net over the past 5 years, most recently at $253.0 million for Q4 2025.

  • Quarterly results put Receivables - Net at $253.0 million for Q4 2025, changed 0.39% from a year ago — trailing twelve months through Dec 2025 was $253.0 million (changed 0.39% YoY), and the annual figure for FY2025 was $253.0 million, changed 0.39%.
  • Receivables - Net for Q4 2025 was $253.0 million at Indivior Pharmaceuticals, down from $259.0 million in the prior quarter.
  • Over the last five years, Receivables - Net for INDV hit a ceiling of $259.0 million in Q3 2025 and a floor of $202.0 million in Q4 2021.
  • Median Receivables - Net over the past 5 years was $248.0 million (2025), compared with a mean of $240.6 million.
  • Biggest five-year swings in Receivables - Net: grew 15.45% in 2023 and later fell 0.39% in 2025.
  • Indivior Pharmaceuticals' Receivables - Net stood at $202.0 million in 2021, then rose by 8.91% to $220.0 million in 2022, then grew by 15.45% to $254.0 million in 2023, then changed by 0.0% to $254.0 million in 2024, then decreased by 0.39% to $253.0 million in 2025.
  • The last three reported values for Receivables - Net were $253.0 million (Q4 2025), $259.0 million (Q3 2025), and $240.0 million (Q2 2025) per Business Quant data.